{
  "symbol": "AMGN",
  "year": 2025,
  "Period": "Q1",
  "report_type": "Q10",
  "metrics": {
    "mdna_sentiment": 0.0,
    "outlook_sentiment": 0.1542,
    "forward_ratio": 1.0,
    "hedge_ratio": 0.211
  },
  "top_positive": [
    {
      "sent": "24 Impact of hedging transactions The following tables summarize the amounts recorded in income and expense line items and the effects thereon from fair value and cash flow hedging, including discontinued hedging relationships (in millions): Three months ended June 30, 2025 Six months ended June 30, 2025 Product sales Other (expense) income, net Interest expense, net Product sales Other (expense) income, net Interest expense, net Total amounts recorded in income and (expense) line items presented in the Condensed Consolidated Statements of Income $ 8,771 $ ( 394 ) $ ( 694 ) $ 16,644 $ 1,124 $ ( 1,417 ) The effects of cash flow and fair value hedging: Gains on cash flow hedging relationships reclassified out of AOCI: Foreign currency forward contracts $ 12 $ \u2014 $ \u2014 $ 68 $ \u2014 $ \u2014 Cross-currency swap contracts $ \u2014 $ 172 $ \u2014 $ \u2014 $ 255 $ \u2014 (Losses) gains on fair value hedging relationships\u2014interest rate swap agreements: Hedged items (1) $ \u2014 $ \u2014 $ ( 61 ) $ \u2014 $ \u2014 $ ( 157 ) Derivatives designated as hedging instruments $ \u2014 $ \u2014 $ 75 $ \u2014 $ \u2014 $ 187 Three months ended June 30, 2024 Six months ended June 30, 2024 Product sales Other (expense) income, net Interest expense, net Product sales Other (expense) income, net Interest expense, net Total amounts recorded in income and (expense) line items presented in the Condensed Consolidated Statements of Income $ 8,041 $ ( 307 ) $ ( 808 ) $ 15,159 $ ( 542 ) $ ( 1,632 ) The effects of cash flow and fair value hedging: Gains (losses) on cash flow hedging relationships reclassified out of AOCI: Foreign currency forward contracts $ 55 $ \u2014 $ \u2014 $ 106 $ \u2014 $ \u2014 Cross-currency swap contracts $ \u2014 $ ( 3 ) $ \u2014 $ \u2014 $ ( 34 ) $ \u2014 (Losses) gains on fair value hedging relationships\u2014interest rate swap agreements: Hedged items (1) $ \u2014 $ \u2014 $ ( 18 ) $ \u2014 $ \u2014 $ 31 Derivatives designated as hedging instruments $ \u2014 $ \u2014 $ 36 $ \u2014 $ \u2014 $ 8 __________ (1) Gains (losses) on hedged \n flow effects of our derivative contracts in the Condensed Consolidated Statements of Cash Flows are included in Net cash provided by operating activities, except for the settlement of notional amounts of cross-currency swaps, which are included in Net cash used in financing activities.",
      "score": 0.9903
    },
    {
      "sent": "In addition, our revolving credit agreement and term loan credit agreement include a financial covenant that requires us to maintain a specified minimum interest coverage ratio of (i) the sum of consolidated net income, interest expense, provision for income taxes, depreciation expense, amortization expense, unusual or nonrecurring charges and other noncash items (consolidated earnings before interest, taxes, depreciation and amortization) to (ii) Consolidated Interest Expense, each as defined and described in the respective agreements.",
      "score": 0.9776
    },
    {
      "sent": "In addition, our revolving credit agreement and term loan credit agreement include a financial covenant that requires us to maintain a specified minimum interest coverage ratio of (i) the sum of consolidated net income, interest expense, provision for income taxes, depreciation expense, amortization expense, unusual or nonrecurring charges and other noncash items (consolidated earnings before interest, taxes, depreciation and amortization) to (ii) Consolidated Interest Expense, each as defined and described in the respective agreements.",
      "score": 0.9776
    }
  ],
  "top_negative": [
    {
      "sent": "Pressures to decrease drug expenditures may intensify as governments take actions to address budgets strained by high inflation and weak economic conditions, including in Europe where the effects of the Russia\u2013Ukraine conflict have challenged the economies in that region.",
      "score": -0.8625
    },
    {
      "sent": "T hese conflicts, in addition to other geopolitical tensions, may also precipitate or amplify the other risks described herein, including risks relating to cybersecurity, global economic conditions, clinical trials and supply chains, which could adversely affect our business, operations and financial condition and results.",
      "score": -0.8519
    },
    {
      "sent": "T hese conflicts, in addition to other geopolitical tensions, may also precipitate or amplify the other risks described herein, including risks relating to cybersecurity, global economic conditions, clinical trials and supply chains, which could adversely affect our business, operations and financial condition and results.",
      "score": -0.8519
    }
  ],
  "forward_snippets": [
    "OBBBA The One Big Beautiful Bill Act OECD Organisation for Economic Co-operation and Development PBM pharmacy benefit manager PDAB Prescription Drug Affordability Board R&D research and development RANKL receptor activator of nuclear factor kappa-B ligand RAR Revenue Agent Report Research and Early Pipeline R&D expenses incurred in activities substantially in support of early research through the completion of phase 1 clinical trials, including drug discovery, toxicology, pharmacokinetics and drug metabolism and process development ii Term Description ROW rest of world S&P Standard & Poor\u2019s Financial Services LLC SEC U.S.",
    "OBBBA The One Big Beautiful Bill Act OECD Organisation for Economic Co-operation and Development PBM pharmacy benefit manager PDAB Prescription Drug Affordability Board R&D research and development RANKL receptor activator of nuclear factor kappa-B ligand RAR Revenue Agent Report Research and Early Pipeline R&D expenses incurred in activities substantially in support of early research through the completion of phase 1 clinical trials, including drug discovery, toxicology, pharmacokinetics and drug metabolism and process development ii Term Description ROW rest of world S&P Standard & Poor\u2019s Financial Services LLC SEC U.S.",
    "OBBBA The One Big Beautiful Bill Act OECD Organisation for Economic Co-operation and Development PBM pharmacy benefit manager PDAB Prescription Drug Affordability Board R&D research and development RANKL receptor activator of nuclear factor kappa-B ligand RAR Revenue Agent Report Research and Early Pipeline R&D expenses incurred in activities substantially in support of early research through the completion of phase 1 clinical trials, including drug discovery, toxicology, pharmacokinetics and drug metabolism and process development ii Term Description ROW rest of world S&P Standard & Poor\u2019s Financial Services LLC SEC U.S.",
    "We expect the adoption of this new standard to result in incremental disclosures to the notes to our financial statements.",
    "We expect that the IRS will begin its audit of 2019-2022 in 2025 or early 2026, and we believe that 12 it may seek to continue to audit similar issues related to the allocation of income between the United States and our foreign jurisdictions."
  ],
  "curated_text": "Symbol: AMGN. Year: 2025. Period: Q1. ReportType: Q10. Section: Management Discussion and Analysis (MD&A). Key metrics include sentiment, forward outlook, and risk hedging.  Top positive sentences: 24 Impact of hedging transactions The following tables summarize the amounts recorded in income and expense line items and the effects thereon from fair value and cash flow hedging, including discontinued hedging relationships (in millions): Three months ended June 30, 2025 Six months ended June 30, 2025 Product sales Other (expense) income, net Interest expense, net Product sales Other (expense) income, net Interest expense, net Total amounts recorded in income and (expense) line items presented in the Condensed Consolidated Statements of Income $ 8,771 $ ( 394 ) $ ( 694 ) $ 16,644 $ 1,124 $ ( 1,417 ) The effects of cash flow and fair value hedging: Gains on cash flow hedging relationships reclassified out of AOCI: Foreign currency forward contracts $ 12 $ \u2014 $ \u2014 $ 68 $ \u2014 $ \u2014 Cross-currency swap contracts $ \u2014 $ 172 $ \u2014 $ \u2014 $ 255 $ \u2014 (Losses) gains on fair value hedging relationships\u2014interest rate swap agreements: Hedged items (1) $ \u2014 $ \u2014 $ ( 61 ) $ \u2014 $ \u2014 $ ( 157 ) Derivatives designated as hedging instruments $ \u2014 $ \u2014 $ 75 $ \u2014 $ \u2014 $ 187 Three months ended June 30, 2024 Six months ended June 30, 2024 Product sales Other (expense) income, net Interest expense, net Product sales Other (expense) income, net Interest expense, net Total amounts recorded in income and (expense) line items presented in the Condensed Consolidated Statements of Income $ 8,041 $ ( 307 ) $ ( 808 ) $ 15,159 $ ( 542 ) $ ( 1,632 ) The effects of cash flow and fair value hedging: Gains (losses) on cash flow hedging relationships reclassified out of AOCI: Foreign currency forward contracts $ 55 $ \u2014 $ \u2014 $ 106 $ \u2014 $ \u2014 Cross-currency swap contracts $ \u2014 $ ( 3 ) $ \u2014 $ \u2014 $ ( 34 ) $ \u2014 (Losses) gains on fair value hedging relationships\u2014interest rate swap agreements: Hedged items (1) $ \u2014 $ \u2014 $ ( 18 ) $ \u2014 $ \u2014 $ 31 Derivatives designated as hedging instruments $ \u2014 $ \u2014 $ 36 $ \u2014 $ \u2014 $ 8 __________ (1) Gains (losses) on hedged \n flow effects of our derivative contracts in the Condensed Consolidated Statements of Cash Flows are included in Net cash provided by operating activities, except for the settlement of notional amounts of cross-currency swaps, which are included in Net cash used in financing activities. In addition, our revolving credit agreement and term loan credit agreement include a financial covenant that requires us to maintain a specified minimum interest coverage ratio of (i) the sum of consolidated net income, interest expense, provision for income taxes, depreciation expense, amortization expense, unusual or nonrecurring charges and other noncash items (consolidated earnings before interest, taxes, depreciation and amortization) to (ii) Consolidated Interest Expense, each as defined and described in the respective agreements. In addition, our revolving credit agreement and term loan credit agreement include a financial covenant that requires us to maintain a specified minimum interest coverage ratio of (i) the sum of consolidated net income, interest expense, provision for income taxes, depreciation expense, amortization expense, unusual or nonrecurring charges and other noncash items (consolidated earnings before interest, taxes, depreciation and amortization) to (ii) Consolidated Interest Expense, each as defined and described in the respective agreements. Top negative sentences: Pressures to decrease drug expenditures may intensify as governments take actions to address budgets strained by high inflation and weak economic conditions, including in Europe where the effects of the Russia\u2013Ukraine conflict have challenged the economies in that region. T hese conflicts, in addition to other geopolitical tensions, may also precipitate or amplify the other risks described herein, including risks relating to cybersecurity, global economic conditions, clinical trials and supply chains, which could adversely affect our business, operations and financial condition and results. T hese conflicts, in addition to other geopolitical tensions, may also precipitate or amplify the other risks described herein, including risks relating to cybersecurity, global economic conditions, clinical trials and supply chains, which could adversely affect our business, operations and financial condition and results. Forward-looking snippets: OBBBA The One Big Beautiful Bill Act OECD Organisation for Economic Co-operation and Development PBM pharmacy benefit manager PDAB Prescription Drug Affordability Board R&D research and development RANKL receptor activator of nuclear factor kappa-B ligand RAR Revenue Agent Report Research and Early Pipeline R&D expenses incurred in activities substantially in support of early research through the completion of phase 1 clinical trials, including drug discovery, toxicology, pharmacokinetics and drug metabolism and process development ii Term Description ROW rest of world S&P Standard & Poor\u2019s Financial Services LLC SEC U.S. OBBBA The One Big Beautiful Bill Act OECD Organisation for Economic Co-operation and Development PBM pharmacy benefit manager PDAB Prescription Drug Affordability Board R&D research and development RANKL receptor activator of nuclear factor kappa-B ligand RAR Revenue Agent Report Research and Early Pipeline R&D expenses incurred in activities substantially in support of early research through the completion of phase 1 clinical trials, including drug discovery, toxicology, pharmacokinetics and drug metabolism and process development ii Term Description ROW rest of world S&P Standard & Poor\u2019s Financial Services LLC SEC U.S. OBBBA The One Big Beautiful Bill Act OECD Organisation for Economic Co-operation and Development PBM pharmacy benefit manager PDAB Prescription Drug Affordability Board R&D research and development RANKL receptor activator of nuclear factor kappa-B ligand RAR Revenue Agent Report Research and Early Pipeline R&D expenses incurred in activities substantially in support of early research through the completion of phase 1 clinical trials, including drug discovery, toxicology, pharmacokinetics and drug metabolism and process development ii Term Description ROW rest of world S&P Standard & Poor\u2019s Financial Services LLC SEC U.S. We expect the adoption of this new standard to result in incremental disclosures to the notes to our financial statements. We expect that the IRS will begin its audit of 2019-2022 in 2025 or early 2026, and we believe that 12 it may seek to continue to audit similar issues related to the allocation of income between the United States and our foreign jurisdictions."
}